Health Care [ 2/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 26 | -0.48 Decreased by -20.00% | -0.54 Increased by +11.11% |
| Mar 13, 26 | -0.45 Increased by +16.67% | -0.62 Increased by +26.90% |
| Nov 12, 25 | -0.55 Increased by +62.33% | -0.52 Decreased by -5.77% |
| Aug 11, 25 | -0.46 Increased by +79.23% | -0.43 Decreased by -6.98% |
| May 14, 25 | -0.40 Decreased by -185.71% | -0.44 Increased by +9.09% |
| Mar 6, 25 | -0.54 Increased by +40.08% | -0.41 Decreased by -31.71% |
| Nov 13, 24 | -1.46 Decreased by -23.12% | -0.32 Decreased by -356.25% |
| Aug 27, 24 | -2.22 Decreased by -79.73% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -31.82 M Decreased by -51.53% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by N/A% | -29.58 M Increased by +11.41% | Decreased by N/A% - |
| Sep 30, 25 | 0.00 Decreased by N/A% | -30.28 M Decreased by -5.78% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -24.57 M Decreased by -10.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -21.00 M Decreased by -945.25% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | N/A Decreased by N/A% | -33.39 M Decreased by -2.97 K% | - - |
| Sep 30, 24 | 0.00 Decreased by N/A% | -28.62 M Decreased by -1.91 K% | Decreased by N/A% - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -22.24 M Decreased by -1.40 K% | Decreased by N/A% - |